Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058856 | 0.86 | ADORA2A (0.45) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL2611082 | 0.82 | ADORA2A (0.40) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL1191900 | 0.82 | ADORA2A (0.40) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL25393852 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPK1ADORA2AALOX15NPSR1 | |
| SCHEMBL1192753 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL25391427 | 0.79 | SLC29A1 (0.41) | SMN1; SMN2MAPK1ADORA2AALOX15ADORA3 | |
| SCHEMBL1192716 | 0.79 | ADORA2A (0.38) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL1192253 | 0.79 | MAPK1 (0.40) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL1192244 | 0.78 | ADORA2A (0.37) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 | |
| SCHEMBL2674349 | 0.78 | PIK3CA (0.40) | SMN1; SMN2MAPK1ADORA2AALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2158207-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. Hoffmann-Roche AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PDPK1, PIK3CA, PI4KA | SMN1; SMN2 3181/4885MAPK1 83/4885ADORA2A 1206/4885 |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PIK3CA, PIK3CD, PI4KA | SMN1; SMN2 4043/4885MAPK1 253/4885ADORA2A 2464/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | SMN1; SMN2 2134/4885MAPK1 694/4885ADORA2A 555/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | SMN1; SMN2 2248/4885MAPK1 696/4885ADORA2A 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.